Display Settings:

Format
Items per page

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 16

1.

Malignant tumor of breast

A primary or metastatic malignant neoplasm involving the breast. The vast majority of cases are carcinomas arising from the breast parenchyma or the nipple. Malignant breast neoplasms occur more frequently in females than in males. [from NCI]

MedGen UID:
651
Concept ID:
C0006142
Neoplastic Process
2.

Breast carcinoma

The presence of a `carcinoma` (MPATH:549) of the `breast` (FMA:9601). [from HPO]

MedGen UID:
428324
Concept ID:
CN002714
Finding
3.

Neoplasm of breast

Tumors or cancer of the human BREAST. [from MeSH]

MedGen UID:
264172
Concept ID:
C1458155
Neoplastic Process
4.

17-allylaminogeldanamycin

MedGen UID:
303858
Concept ID:
C1688521
Pharmacologic Substance
5.

Murine

MedGen UID:
108834
Concept ID:
C0591833
Pharmacologic Substance
6.

Phosphorylation

A process in which a phosphate group is added to a molecule, such as a sugar or a protein. [from NCI]

MedGen UID:
10742
Concept ID:
C0031715
Molecular Function
7.

Dephosphorylation

The process of removing one or more phosphoric (ester or anhydride) residues from a molecule. [ISBN:0198506732] [from GO]

MedGen UID:
463624
Concept ID:
C3160734
Molecular Function
8.

Negative Regulation of G1 Phase

G1 Arrest consists of cellular biochemical mechanisms, responsive to diverse governing conditions (DNA damage, contact inhibition, growth factors, etc.), that control cellular progress through the G1 phase of the cell cycle. G1 progress is controlled by de/phosphorylated cyclin/CDK complexes. During G1, cycD/CDK phosphorylation of Rb/HDAC repressor permits E2F/DP1 transcription of genes that promote the G1/S switch and DNA replication. p53 induces p21 inhibition of cycD/CDK; Mdm2 inhibits p53/p21. TGF-b induces p15 inhibition of cycD/CDK. cAMP induces p27 inhibition of cycD/CDK. GSK3b induction of cycD degradation, and INK4, Kip, and Cdc25A regulate cycD/CDK activity. [from NCI]

MedGen UID:
275923
Concept ID:
C1517342
Molecular Function
9.

Protein dephosphorylation

The process of removing one or more phosphoric residues from a protein. [GOC:hb] [from GO]

MedGen UID:
223888
Concept ID:
C1158884
Molecular Function
10.

Inhibition

MedGen UID:
5809
Concept ID:
C0021469
Molecular Function
11.

Skin and Connective Tissue Diseases

A collective term for diseases of the skin and its appendages and of connective tissue. [from MeSH]

MedGen UID:
59786
Concept ID:
C0175166
Disease or Syndrome
12.

Enzyme activation

Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. [from MeSH]

MedGen UID:
41819
Concept ID:
C0014429
Molecular Function
13.

Disorder of skin

Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.(NCI) [from NCI]

MedGen UID:
20777
Concept ID:
C0037274
Disease or Syndrome
14.

Antineoplastic Agents

NOTE: Includes hormones (AN500) which are exclusively used as antineoplastics (e.g.,tamoxifen). Excludes other hormones (HS000). [from NDF-RT]

MedGen UID:
1984
Concept ID:
C0003392
Pharmacologic Substance
15.

Disorder of breast

disease or disorder of the breast. [from CRISP]

MedGen UID:
652
Concept ID:
C0006145
Disease or Syndrome
16.

CNF1010

MedGen UID:
760448
Concept ID:
C1541784
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...